Diplomat Pharmacy Inc (DPLO) is Reiterated by Mizuho to Neutral, Raises Price Target to $ 33

Diplomat Pharmacy Inc (DPLO) was Reiterated by Mizuho to “Neutral” according to the research note released today. The brokerage firm has raised the Price Target to $ 33 from a previous price target of $30 . Mizuho advised their investors in a research report released on May 11, 2016.

Many Wall Street Analysts have commented on Diplomat Pharmacy Inc. Avondale Initiated Diplomat Pharmacy Inc on Apr 19, 2016 to “Mkt Outperform”, Price Target of the shares are set at $38.Diplomat Pharmacy Inc was Initiated by Credit Suisse to “Neutral” on Mar 16, 2016. Diplomat Pharmacy Inc was Downgraded by JP Morgan to ” Neutral” on Mar 1, 2016.

On the company’s financial health, Diplomat Pharmacy Inc reported $0.23 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on May 9, 2016. Analyst had a consensus of $0.18. The company had revenue of $995.90 million for the quarter, compared to analysts expectations of $982.32 million. The company’s revenue was up 59.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.09 EPS.

Diplomat Pharmacy Inc closed down -0.54 points or -1.85% at $28.63 with 7,12,701 shares getting traded on Friday. Post opening the session at $29.19, the shares hit an intraday low of $28.2 and an intraday high of $29.44 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

In a different news, on May 2, 2016, Atheer A Kaddis (EVP of Sales & Strategic Align) sold 12,325 shares at $30.17 per share price. According to the SEC, on Dec 8, 2015, Philip R Hagerman (Chairman and CEO) sold 2,300,000 shares at $33.60 per share price. On Dec 2, 2015, Gary W Kadlec (President) sold 30,000 shares at $35.08 per share price, according to the Form-4 filing with the securities and exchange commission.

Diplomat Pharmacy Inc. (Diplomat) is an independent specialty pharmacy in the United States. The Company provides specialty pharmacy support services to a national network of retailers and independent pharmacy groups hospitals and health systems. The Company offers services in Specialty Drug Dispensing which includes its specialty infusion pharmacy services. The specialty drug dispensing services include Patient Care Coordination Clinical Services Compliance and Persistency Programs Patient Financial Assistance Specialty Pharmacy Training/Consulting (Diplomat University) Benefits Investigation Prior Authorization Risk Evaluation and Medication Strategy (REMS) Retail Specialty Services Hospital and Health System Services and Hub Services. The Company help patients adhere to complicated medication therapies process refills and manage any side effects and insurance concerns to ensure they get the standard of care.

Diplomat Pharmacy Inc

Leave a Reply

Diplomat Pharmacy Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Diplomat Pharmacy Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.